Triple negative breast cancer, HRD, microtubule inhibitors, eribulin, response, resistance
non-small cell lung cancer, EGFR mutation, osimertinib, platinum-based chemotherapy, pemetrexed
lung cancer, COPD, LABA, LAMA, ICS, immune checkpoint inhibitor